Endurance Wealth Management’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-159,703
| Closed | -$2.42M | – | 672 |
|
|
2022
Q3 | $2.42M | Sell |
159,703
-7,800
| -5% | -$90.7K | 0.4% | 56 |
|
|
2022
Q2 | $1.26M | Sell |
167,503
-5,000
| -3% | -$35.2K | 0.19% | 86 |
|
|
2022
Q1 | $1.57M | Buy |
172,503
+14,334
| +9% | +$110K | 0.2% | 81 |
|
|
2021
Q4 | $1.11M | Sell |
158,169
-46,901
| -23% | -$491K | 0.12% | 111 |
|
|
2021
Q3 | $2.34M | Buy |
205,070
+27,611
| +16% | +$404K | 0.26% | 83 |
|
|
2021
Q2 | $2.84M | Buy |
177,459
+49,859
| +39% | +$855K | 0.32% | 74 |
|
|
2021
Q1 | $2.28M | Buy |
127,600
+28,160
| +28% | +$486K | 0.27% | 82 |
|
|
2020
Q4 | $1.34M | Buy |
99,440
+97,090
| +4,131% | +$1.17M | 0.17% | 91 |
|
|
2020
Q3 | $28K | Sell |
2,350
-200
| -8% | -$2.44K | ﹤0.01% | 363 |
|
|
2020
Q2 | $37K | Sell |
2,550
-500
| -16% | -$7.4K | 0.01% | 340 |
|
|
2020
Q1 | $41K | Buy |
3,050
+750
| +33% | +$14.2K | 0.01% | 305 |
|
|
2019
Q4 | $55K | Sell |
2,300
-300
| -12% | -$6.21K | 0.01% | 275 |
|
|
2019
Q3 | $50K | Buy |
2,600
+1,650
| +174% | +$37.8K | 0.01% | 280 |
|
|
2019
Q2 | $28K | Buy |
950
+450
| +90% | +$17.3K | ﹤0.01% | 315 |
|
|
2019
Q1 | $24K | Hold |
500
| – | – | ﹤0.01% | 318 |
|
|
2018
Q4 | $18K | Buy |
500
+200
| +67% | +$9.38K | ﹤0.01% | 327 |
|
|
2018
Q3 | $18K | Hold |
300
| – | – | ﹤0.01% | 353 |
|
|
2018
Q2 | $20K | Hold |
300
| – | – | ﹤0.01% | 349 |
|
|
2018
Q1 | $16K | Buy |
300
+100
| +50% | +$5.59K | ﹤0.01% | 388 |
|
|
2017
Q4 | $12K | Hold |
200
| – | – | ﹤0.01% | 401 |
|
|
2017
Q3 | $10K | Buy |
+200
| New | +$10.9K | ﹤0.01% | 411 |
|
Endurance Wealth Management's AERI Position: Q4 2022 in Review
Endurance Wealth Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 159,703 shares — an estimated $2.42M sold.
Endurance Wealth Management first reported a position in AERI in Q3 2017 and held it in 21 quarters. The position peaked at $2.84M in Q2 2021. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Endurance Wealth Management reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Endurance Wealth Management sold 159,703 Aerie Pharmaceuticals shares in Q4 2022, an estimated $2.42M.
- Endurance Wealth Management first reported a position in Aerie Pharmaceuticals in Q3 2017 and held it in 21 quarters.
- Endurance Wealth Management's Aerie Pharmaceuticals position peaked at $2.84M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Endurance Wealth Management's 13F filing for Q4 2022, filed 1 Feb 2023.